NCT03478111View on ClinicalTrials.gov

CMAB008 With MTX Therapy in Adult Patients With Moderately to Severely Active Rheumatoid Arthritis

PHASE3CompletedINTERVENTIONAL
Enrollment

390

Participants

Timeline

Start Date

March 30, 2018

Primary Completion Date

June 23, 2019

Study Completion Date

August 27, 2019

Conditions
Rheumatoid Arthritis
Interventions
DRUG

CMAB008

the study drug

DRUG

MTX

basic therapy drug

DRUG

Remicade

active comparator

Trial Locations (1)

100044

Peking University People's Hospital, Beijing

All Listed Sponsors
lead

Shanghai Biomabs Pharmaceutical Co., Ltd.

INDUSTRY

NCT03478111 - CMAB008 With MTX Therapy in Adult Patients With Moderately to Severely Active Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter